Product Licensing

Specialty drug company receives U.S. FDA approval for mint flavor nicotine gum

Published in Medical Letter on the CDC and FDA, September 5th, 2004

Watson Pharmaceuticals, Inc. (WPI), a specialty pharmaceutical company, has received approval from the United States Food and Drug Administration (FDA) on its abbreviated new drug application (ANDA) for nicotine polacrilex gum, mint flavor, in the 2 and 4 mg strengths.

Nicotine polacrilex gum, mint flavor, is the generic version of GlaxoSmithKline Consumer Healthcare's Nicorette Mint gum, which is used as an aid to smoking cessation.

The company expects the product to be shipped by the end of the third quarter.

Watson Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, markets, sells and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2004-09-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry